ARQT Arcutis Biotherapeutics, Inc.
P/E
151.76
Forward P/E
26.39
Price/Sales
8.63
Beta
1.58
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Arcutis Biotherapeutics third quarter 2026 revenue of $143.9M doubled expectations despite missing EPS estimates
Arcutis delivered a significant revenue beat driven by rapid ZORYVE adoption across atopic and seborrheic dermatitis markets. While EPS missed expectations due...
Arcutis Biotherapeutics Inc Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
Arcutis Biotherapeutics is expected to report Q3 2026 revenue of $78.20 million and earnings per share of $0.17, while the stock trades at $14.12 against a...
Arcutis Appoints Former AbbVie CMO Dr. Robert Scott to Board of Directors
Arcutis Biotherapeutics announced the appointment of Dr. Robert Scott to its Board of Directors, effective October 23, 2026. The company's board was expanded...